HK Stock Movement | INNOVENT BIO (01801) Rises Nearly 5%, Set to Join Hang Seng Index on Dec 8

Stock News

Nov 24, 2025

INNOVENT BIO (01801) surged nearly 5% intraday, trading at HK$90.65 by press time, up 3.9%, with a turnover of HK$177 million. The catalyst behind the rally stems from the latest quarterly review of the Hang Seng Index Series, announced on November 21, with changes taking effect on December 8, 2025. INNOVENT BIO will be added as a constituent stock, expanding the index count from 88 to 89.

Notably, on November 20, the company disclosed that its Mazdutide injection (a GCG/GLP-1 dual agonist, R&D code: IBI362) achieved primary and all key secondary endpoints in the Phase III GLORY-2 trial targeting moderate-to-severe obesity in China. INNOVENT BIO plans to soon submit a new drug application for the 9mg dose of Mazdutide for adult weight management to regulators.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1194734619"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194734619\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194734619?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194734619","market":"other","top_or_hot":-1,"title":"HK Stock Movement | INNOVENT BIO (01801) Rises Nearly 5%, Set to Join Hang Seng Index on Dec 8","media":"Stock News","content":"<p>INNOVENT BIO (01801) surged nearly 5% intraday, trading at HK$90.65 by press time, up 3.9%, with a turnover of HK$177 million. The catalyst behind the rally stems from the latest quarterly review of the Hang Seng Index Series, announced on November 21, with changes taking effect on December 8, 2025. INNOVENT BIO will be added as a constituent stock, expanding the index count from 88 to 89.</p>\n<p>Notably, on November 20, the company disclosed that its Mazdutide injection (a GCG/GLP-1 dual agonist, R&D code: IBI362) achieved primary and all key secondary endpoints in the Phase III GLORY-2 trial targeting moderate-to-severe obesity in China. INNOVENT BIO plans to soon submit a new drug application for the 9mg dose of Mazdutide for adult weight management to regulators.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | INNOVENT BIO (01801) Rises Nearly 5%, Set to Join Hang Seng Index on Dec 8</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | INNOVENT BIO (01801) Rises Nearly 5%, Set to Join Hang Seng Index on Dec 8\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-24 09:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOVENT BIO (01801) surged nearly 5% intraday, trading at HK$90.65 by press time, up 3.9%, with a turnover of HK$177 million. The catalyst behind the rally stems from the latest quarterly review of the Hang Seng Index Series, announced on November 21, with changes taking effect on December 8, 2025. INNOVENT BIO will be added as a constituent stock, expanding the index count from 88 to 89.</p>\n<p>Notably, on November 20, the company disclosed that its Mazdutide injection (a GCG/GLP-1 dual agonist, R&D code: IBI362) achieved primary and all key secondary endpoints in the Phase III GLORY-2 trial targeting moderate-to-severe obesity in China. INNOVENT BIO plans to soon submit a new drug application for the 9mg dose of Mazdutide for adult weight management to regulators.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828805.USD","symbol_name":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","start_time":0,"source_url":"","article_id":"1194734619","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194734619","pubTimestamp":1763948653,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOVENT BIO (01801) surged nearly 5% intraday, trading at HK$90.65 by press time, up 3.9%, with a turnover of HK$177 million. The catalyst behind the rally stems from the latest quarterly review of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","01801":"信达生物","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1589":"北水核心资产","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK1161":"生物科技","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC"},"translate_title":"港股动向|信达生物(01801)涨近5%拟于12月8日加入恒生指数","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"INNOVENT BIO (01801) surged nearly 5% intraday, trading at HK$90.65 by press time, up 3.9%, with a turnover of HK$177 million. The catalyst behind the rally stems from the latest quarterly review of the Hang Seng Index Series, announced on November 21, with changes taking effect on December 8, 2025. INNOVENT BIO will be added as a constituent stock, expanding the index count from 88 to 89.\nNotably, on November 20, the company disclosed that its Mazdutide injection (a GCG/GLP-1 dual agonist, R&D code: IBI362) achieved primary and all key secondary endpoints in the Phase III GLORY-2 trial targeting moderate-to-severe obesity in China. INNOVENT BIO plans to soon submit a new drug application for the 9mg dose of Mazdutide for adult weight management to regulators.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}